The Asia Pacific Amniotic Products Market would witness market growth of 8.3% CAGR during the forecast period (2023-2030).
The market is expanding due to the increased public knowledge of using transplants based on amniotic membranes. Additionally, the aging of the population and the expansion of technology in the healthcare industry are the main drivers of market expansion. As a result, growing government funding and initiatives drive this industry. One of the leading causes of morbidity is non-fatal burn injuries. Burns typically happen at home or the workplace. Consequently, more accidents and trauma occur, which in turn helps the market.
Major amniotic product market players have access to enormous growth prospects in emerging nations. This can be ascribed to a lack of legislative restrictions, advancements in the healthcare system, an increase in the number of patients, and rising healthcare costs. In addition, compared to industrialized nations, regulatory rules in the Asia-Pacific area are more flexible and business-friendly. This reason has compelled significant market players to concentrate on the rising economies and the escalating competition in developed markets.
Over the past three decades, diabetes has gradually increased in both India and the rest of the world, with India contributing significantly to the overall burden. In India, disease patterns have changed due to an epidemiological shift. According to the IDF's seventh edition of the Diabetes Atlas (11.43 cr.), China has the highest prevalence of diabetes. With 114 million cases, China has the highest prevalence of diabetes globally, with type 2 accounting for the majority.
According to the IDF in 2019, the top three countries with the highest number of individuals with diabetes are China (116.4 million), India (77.0 million), This trend is expected to continue in 2030 and 2045, with China (140.5 and 147.2 million) and India (101.0 and 134.2 million) continuing to have the highest burden of diabetes. As a result of the rising prevalence of diabetes across the Asia Pacific region, the market is anticipated to grow.
The China market dominated the Asia Pacific Amniotic Products Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $105.2 Million by 2030. The Japan market is anticipated to grow at a CAGR of 7.7% during (2023 - 2030). Additionally, The India market would register a CAGR of 9.1% during (2023 - 2030).
Based on Type, the market is segmented into Cryopreserved Amniotic Membranes and Dehydrated Amniotic Membranes. Based on Application, the market is segmented into Wound Care, Ophthalmology, Orthopedics, and Others. Based on End User, the market is segmented into Hospital & Ambulatory Surgical Centers and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Amniotic Products Market is Projected to reach USD 1.6 Billion by 2030, at a CAGR of 7.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include MiMedx Group, Inc., Integra LifeSciences Holdings Corporation, Organogenesis Holdings, Inc., Amnio technology LLC, Alliqua Biomedical, Inc., Human Regenerative Technologies, LLC (Skye Biologics Holdings Company), Corza Ophthalmology (Corza Medical, Inc.), BioTissue Holdings, Inc., Applied Biologics LLC
By Type
By Application
By End User
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 